Brand name: Anti-Fungal (Pharmacy Health)
Anti-Fungal (Pharmacy Health) is a medicine containing the active ingredient(s) clotrimazole. On this page you will find out more about Anti-Fungal (Pharmacy Health), including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: clotrimazole
Information for medicine and pack size:
Anti-Fungal (Pharmacy Health) 1% cream, 50 g
Consumer Medicine Information leaflet:
No consumer medicine information leaflet was found for the pack size you selected. It may be unavailable or there may be a technical problem. You should speak to your pharmacist, healthcare professional, or call healthdirect on 1800 022 222 for more information.
What this medicine is for
For the treatment of fungal skin conditions such as tinea, athlete's foot, jock itch, ringworm and candidal infections including nappy rash.
Table of characteristics
| Active ingredient | |
|---|---|
| Visual appearance | White, smooth, homogenous cream. |
| Dosage Form | Cream |
| Route of administration | Topical |
| Medicine schedule |
20 gram: Pharmacy Medicine (Over the counter)
30 gram: Pharmacy Medicine (Over the counter)
50 gram: Pharmacy Medicine (Over the counter)
|
There is one type of pack available.
Pack type 1
| Type | Tube |
|---|---|
| Storage temperature | Store below 25 degrees Celsius |
| Storage conditions | No information available |
| Life time | 2 Years |
We were unable to verify that this medicine is available on the PBS (Pharmaceutical Benefits Scheme). Please consult your pharmacist if you need further information
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.
Need more information?
These trusted information partners have more on this topic.
Found 361 results
Vulval conditions fact sheet - Women's Health Queensland Wide
Women's Health Queensland Wide Inc (Women's Health) is a not for profit health promotion, information and education service for women and health professionals throughout Queensland.
Read more on Women's Health Queensland Wide website
Kids' Health - Topics - Nails
Nails are made in folds of the skin near the ends of our fingers and toes. They start to grow in the nail root (the part of the nail that is still underneath the skin) and then they slide out over the nail bed towards the end of the toes and fingers. Near the end of the nail it separates from the skin underneath it, where the nail colour changes from pink to white.
Read more on Women's and Children's Health Network website
Mould and dampness
Mould and dampness in homes may cause health problems.
Read more on WA Health website
Kids' Health - Topics - Look after your feet
You run, walk, skip, ride bikes and do all sorts of things that you would find it really hard to do without them. Most of the time you never even notice them.
Read more on Women's and Children's Health Network website
Voriconazole APOTEX Tablets - myDr.com.au
Voriconazole APOTEX Tablets - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Fluconazole Solution for infusion - myDr.com.au
Fluconazole Solution for infusion - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Fluconazole Hexal Injection Solution for infusion - myDr.com.au
Fluconazole Hexal Injection Solution for infusion - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Femazole Duo Combination pack - myDr.com.au
Femazole Duo Combination pack - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Fluzole Capsules - myDr.com.au
Fluzole Capsules - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Vagiclear Duo Combination pack - myDr.com.au
Vagiclear Duo Combination pack - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Found 10 results
Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush) | Cochrane
Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush)
Read more on Cochrane (Australasian Centre) website
Oral potassium iodide for the treatment of sporotrichosis | Cochrane
Potassium iodide is an anti-fungal drug listed in the World Health Organization (WHO) essential drug list and generally thought to be the first choice for cutaneous sporotrichosis including fixed and lymphocutaneous types, in developing countries. No randomised controlled trials (RCTs) of oral potassium iodide versus placebo were found and thus its efficacy and safety could not be analysed in this review. There is a need for randomised placebo controlled trials of oral potassium iodide in this area.
Read more on Cochrane (Australasian Centre) website
Cyclosporine for treatment of active Crohn's disease | Cochrane
The results of this review demonstrate that low dose oral cyclosporine is not effective for treatment of active Crohn's disease. Studies indicate that Crohn's patients treated with low dose (5 mg/kg/day) oral cyclosporine could experience side effects including kidney problems. Therefore the use of this medication for the treatment of chronic active Crohn's disease is not advisable. Higher oral doses and injections of cyclosporine have not been sufficiently evaluated. Larger doses of cyclosporine are not likely to be useful for the long-term management of Crohn's disease due to the risk of kidney damage and the availability of other proven medications.
Read more on Cochrane (Australasian Centre) website
Artemether injection for treating people with severe malaria | Cochrane
In this review, researchers from The Cochrane Collaboration examined the effects of treating people that have severe malaria with artemether injected intramuscularly, and compared it to treatment with other antimalarial drugs given intramuscularly or intravenously. After searching for relevant trials up to 9 April 2014, we included 18 randomized controlled trials that recruited 2662 adults and children and were conducted mainly in Africa and Asia.
Read more on Cochrane (Australasian Centre) website
Which amphotericin B formulation better preserves kidney function among people with fungal infection? | Cochrane
Which amphotericin B formulation better preserves kidney function among people with fungal infection?
Read more on Cochrane (Australasian Centre) website
Prophylaxis with Immunoglobulin G (IgG), anti CMV vaccine or interferon do not significantly reduce CMV disease and CMV-associated mortality in solid organ transplant recipients | Cochrane
Prophylaxis with Immunoglobulin G (IgG), anti CMV vaccine or interferon do not significantly reduce CMV disease and CMV-associated mortality in solid organ transplant recipients
Read more on Cochrane (Australasian Centre) website
Antiviral drugs used as protective and preventive therapy reduce CMV disease and CMV-associated deaths in solid organ transplant recipients | Cochrane
Antiviral drugs used as protective and preventive therapy reduce CMV disease and CMV-associated deaths in solid organ transplant recipients
Read more on Cochrane (Australasian Centre) website
Pre-emptive treatment with antiviral agents can help to reduce the risk of cytomegalovirus disease | Cochrane
Cytomegalovirus (CMV) is the most common cause of viral disease in people who have received kidney, heart, liver, lung or pancreas transplants (solid organ transplants). CMV is a major cause of illness and death during the first six months after transplantation. Characteristics of CMV include fever, very low white blood cell counts (leucopenia) and very low numbers of platelets (thrombocytopenia) with or without specific organ involvement.
Read more on Cochrane (Australasian Centre) website
5-FU for genital warts in nonimmunocompromised individuals | Cochrane
Genital warts is one of the most common types of sexually transmitted infection, with an estimated occurrence of about 32 million cases worldwide each year. The warts affect the genital area and cause such symptoms as itching, burning, discomfort, pain, or bleeding with intercourse. Because of the recurrence and the stigma associated with genital warts, frequently there are psychological burdens associated with the disease that possibly could become traumatic as feeling of shame, worry, fear, anger, and lowered self-esteem develop. Lesions can spread on one person and because they are easily spread between people, genital warts potentially can be a serious public health problem. There are many options for treating genital warts, but none so far are superior to the others. At this time, there is no available evidence that treatment efficiently eliminates genital warts or hinders its progression to malignancy. This review evaluated theeffectiveness and safety of topical 5-FU for treatment of genital warts in nonimmunocompromised individuals. Evidence from the studies we reviewed showed that 5-FU had better results for cure than placebo or no treatment; MCSA; and Podophylin 2%, 4% or 25%. No statistical difference was found when 5-FU was compared with CO2 Laser treatment, and results were poor when 5-FU was compared with 5-FU + INF-2a (high dose) or 5-FU + CO2 Laser INF-2a (high dose). The weak point of this review was the great variability in the methods and quality of the studies that we included.
Read more on Cochrane (Australasian Centre) website
Intravenous N-acetylcysteine compared to placebo for treatment of systemic inflammatory response syndrome and sepsis in seriously ill adults | Cochrane
Intravenous N-acetylcysteine compared to placebo for treatment of systemic inflammatory response syndrome and sepsis in seriously ill adults
Read more on Cochrane (Australasian Centre) website
